Octoplus « Terug naar discussie overzicht

Ontwikkelingen Locteron

35 Posts, Pagina: « 1 2 | Laatste

Omlaag ↓

[verwijderd] 7 juni 2007 18:45

The overall hepatitis C market is expected to grow to as much as $10 billion in the next few years, making it a competitive space for biotech and pharma. Among Biolex's potential competitors is Rockville, Md.-based Human Genome Sciences Inc., which has started Phase III with Albuferon, a long-acting formulation of interferon that, like Locteron, is designed for dosing once every two weeks.

[verwijderd] 7 juni 2007 19:02

Dropouts Albuferon ? Iemand een betere uitleg.

( zo als ik het nu begrijp is dit toch goed nieuws voor octoplus of niet)

gr zenzoe

[verwijderd] 7 juni 2007 19:13

Albuferon helpt wel maar met een hoop bijwerkingen.

Ben benieuwd wat locteron deze maand doet.

[verwijderd] 7 juni 2007 19:16

Human Genome Science Drug Helps Hepatitis C Patients (Update2)

By Michelle Fay Cortez

June 7 (Bloomberg) -- Human Genome Sciences Inc. said its experimental drug Albuferon, given every other week, held chronic hepatitis C in check as effectively as weekly treatment with Roche Holding AG's Pegasys.

A study found 58.5 percent of Albuferon patients had no detectable virus in their blood six months after treatment, compared with 57.9 percent of those on Pegasys. Heavier patients who faithfully took the medicine fared better on Albuferon, the Rockville, Maryland-based company said today in a statement.

Four million Americans have hepatitis C, which can cause cirrhosis, liver cancer and death. Human Genome said it is now moving the drug into the final stage of testing. If approved, Albuferon could compete with Roche's Pegasys, which had $400 million in first quarter sales, by offering a less restrictive treatment regime, the researchers said.

Patients may do just as well on Albuferon ``with half the injections and possibly less impairment of quality of life,'' said John McHutchison, lead investigator of the study and professor at Duke University Medical Center in Durham, North Carolina, in a statement.

Human Genome's shares fell 1 cent to $10.45 at 10:54 a.m. New York time in New York Stock Exchange composite trading. The stock has dropped 1.4 percent in the 12 months before today.

In the study, 458 patients were treated for a year, and then followed for an additional six months. The trial was in the second of three stages needed to win U.S. marketing approval.

Less Likely to Miss

Patients getting Albuferon were less likely to miss a week of work or more during therapy, though more dropped out of the study because of side effects. A higher dose appeared slightly less effective and caused even more dropouts, the company said.

Additional details about the study, from the second of three phases generally required for U.S. approval, will be presented at a future medical meeting, the company said. The released results did not identify the drug's side effects.

Human Genome Sciences makes Albuferon by fusing two naturally occurring human blood proteins, albumin and interferon alpha. It is being developed by Human Genome and Novartis AG, the Basel, Switzerland, pharmaceutical company. Under an agreement reached in June, 2006, the two companies will share the costs of development and getting approval to bring the product to market.

About half of patients getting a higher dose of the drug just once a month had a sustained response, Human Genome said. The two companies are planning additional work to test higher doses of the drug given monthly.

To contact the reporter on this story: Michelle Fay Cortez in Minneapolis at mcortez@bloomberg.net .

[verwijderd] 7 juni 2007 23:11

Human Genome Science Drug Helps Hepatitis C Patients (Update3)

By Michelle Fay Cortez

June 7 (Bloomberg) -- Human Genome Sciences Inc. said its experimental drug Albuferon, given every other week, held chronic hepatitis C in check as effectively as weekly treatment with Roche Holding AG's Pegasys.

The company's shares fell 6 percent, the most in six months, after Piper Jaffray & Co. downgraded the stock to market perform from outperform. ``Despite the encouraging data'' on Albuferon, Health Genome Sciences continues to lack a product that will drive profit until at least 2009, New York-based Piper Jaffray said in its report.

The study found 58.5 percent of Albuferon patients had no detectable virus six months after treatment, compared with 57.9 percent of those on Pegasys, a standard treatment. The finding suggests the drug could compete with Pegasys, which had $400 million in first quarter sales, by offering a less restrictive treatment regime, researchers said.

Patients may do just as well on Albuferon ``with half the injections and possibly less impairment of quality of life,'' said John McHutchison, lead investigator of the study and professor at Duke University Medical Center in Durham, North Carolina, in a statement.

The shares of Human Genome Science, based in Rockville, Maryland, fell 63 cents to $9.83 at 4 p.m. New York time in New York Stock Exchange composite trading. The stock has dropped 7.4 percent in the previous 12 months.

Four million Americans have hepatitis C, which can cause cirrhosis, liver cancer and death. Human Genome said it is now moving the drug into the final stage of testing.

485 Patients

In the study, 458 patients were treated for a year, and then followed for an additional six months. The trial was in the second of three stages needed to win U.S. marketing approval.

Patients getting Albuferon were less likely to miss a week of work or more during therapy, though more dropped out of the study because of side effects. A higher dose appeared slightly less effective and caused even more dropouts, the company said.

Additional details about the study, from the second of three phases generally required for U.S. approval, will be presented at a future medical meeting, the company said. The released results did not identify the drug's side effects.

Human Genome Sciences makes Albuferon by fusing two naturally occurring human blood proteins, albumin and interferon alpha. It is being developed by Human Genome and Novartis AG, the Basel, Switzerland, pharmaceutical company. Under an agreement reached in June, 2006, the two companies will share the costs of development and getting approval to bring the product to market.

About half of patients getting a higher dose of the drug just once a month had a sustained response, Human Genome said. The two companies are planning additional work to test higher doses of the drug given monthly.

To contact the reporter on this story: Michelle Fay Cortez in Minneapolis at mcortez@bloomberg.net .

Last

[verwijderd] 7 juni 2007 23:17

De concurent heeft een stap laten liggen volgens mij , als deze maand de uitslag van LOCTERON komt

en die is wel ok staan Octoplus en Biolex op de zelfde hoogte als Human Genome Scienes. Dus volgens mij een hele FASE ingegelopen .

Iemand nog een meening hier over.

of zie ik het nu verkeert.

gr zenzoe

[verwijderd] 12 juni 2007 00:23

Dat zie jij heeel goed zenzoe

Hier een grote aanbeveling voor jou!!

Einde van de week staan we op de 6 euro

[verwijderd] 14 juni 2007 10:01

Jammer dat de laat zo dik word gezet.
Anders weg vrij naar 5.80 .

[verwijderd] 15 juni 2007 13:38

de weg vrij naar de 5.80?
je bedoeld 4.80?
gewoon weer keihard 0.15 eu eraf!
waarom zakt het aandeel de laatste tijd t.o.v de aex?

[verwijderd] 25 juni 2007 21:30

Wat doen de anderen op het HIV gebied
zo lang we wachten op de PB locteron.

By Avram Goldstein

June 25 (Bloomberg) -- Gilead Sciences Inc., the fourth- largest biotechnology company by sales, said its HIV drug Viread met the goal in a second late-stage study evaluating the medication as a treatment for hepatitis B.

The study compared the drug with Hepsera, another Gilead product, the company said today in a statement on Business Wire. Two-thirds of patients taking Viread had a complete response, meaning a reduction in virus levels and a drop in tissue- destroying inflammation, after 48 weeks, the company said. That compares with 12 percent for Hepsera patients.

Gilead, based in Foster City, California, said it aims to file applications with European and U.S. regulators during the fourth quarter for approval of Viread as a hepatitis B treatment. The drug faces a crowded market, analysts said.

``Several compounds are out there, and the market's not that large, so hepatitis B is not going to have a major impact on Viread sales,'' said Keith Haan, an analyst with Sumner Street Research Partners in Boston, in a telephone interview today.

``Viread is one of the more-potent agents and has activity in strains that are resistant'' to other drugs, Haan said.

More than 1 million Americans have chronic hepatitis B and each tear 80,000 are infected with the virus, according to the American Liver Foundation. Worldwide, about 400 million people have the disease. Viread, the most commonly used pill in HIV drug cocktails, is Gilead's third-leading medication, with $161 million in first-quarter sales.

Drugs already approved for chronic hepatitis B treatment include products of Bristol-Myers Squibb Co., GlaxoSmithKline plc, Idenix Pharmaceuticals Inc. and Novartis AG, Haan said..

Viread's expected higher price may make it less attractive than the others, said Geoffrey Porges, an analyst with Sanford C. Bernstein & Co. in New York, in a telephone interview today.

Gilead shares fell 3 cents to $39.21 at 10:44 a.m. New York time in Nasdaq Stock Market composite trading. The stock rose 43 percent in the 12 months through June 22.

www.bloomberg.com/news/industries/hea...

[verwijderd] 25 juni 2007 21:35

Hepatitis Weekly via NewsEdge Corporation :

2007 JUN 25 - (NewsRx.com) -- Research findings, "Human immunodeficiency virus and hepatitis C virus testing services at syringe exchange programs: availability and outcomes," are discussed in a new report. "We described the availability and outcomes of human immunodeficiency virus (HIV) and hepatitis C virus (HCV) testing services at syringe exchange programs throughout California, using interviews with 24 syringe exchange program directors and 560 syringe exchange clients. Both HIV and HCV testing services were available in 62% of programs, 21% had HIV testing only, and 17% had neither," scientists writing in the Journal of Substance Abuse Treatment report.

"Programs administered by health care/social service providers were more likely than independent syringe exchange programs to have HIV and HCV testing services available. Among clients of programs with testing available, clients of illegal programs were significantly less likely than clients of legal programs to have used syringe exchange HIV and HCV testing services. The availability of HIV and HCV testing services at syringe exchange programs varies, and the use of existing testing services by clients is not universal," wrote K.G. Heinzerling and colleagues, University of California.

The researchers concluded: "Efforts to increase both the availability of HIV and HCV testing services at syringe exchange programs and the use of existing testing services are needed."

Heinzerling and colleagues published their study in the Journal of Substance Abuse Treatment (Human immunodeficiency virus and hepatitis C virus testing services at syringe exchange programs: availability and outcomes. Journal of Substance Abuse Treatment, 2007;32(4):423-9).

Additional information can be obtained by contacting K.G. Heinzerling, University of California-Los Angeles, Dept. of Family Medicine and Integrated Substance Abuse Programs, Los Angeles, CA 90095-7087 USA.

The publisher of the Journal of Substance Abuse Treatment can be contacted at: Pergamon-Elsevier Science Ltd., the Boulevard, Langford Lane, Kidlington, Oxford OX5 1GB, England.

<<Hepatitis Weekly -- 06/22/07>>

[verwijderd] 26 juni 2007 13:22

zegt me allemaal nix die engelse tekst
wat ik wel weet dat het aandeel weer hard naar beneden keldert

pim f 26 juni 2007 20:51

quote:
dekker1954 schreef:
zegt me allemaal nix die engelse tekst
wat ik wel weet dat het aandeel weer hard naar beneden keldert

als investeerder speld je jezelf hier een dubbel brevet van onvermogen op. succes verder...

(PS je bijdragen in deze draad bestaan tot driemaal aan toe een vrij stompzinnige constatering dat de prijs van dit aandeel naar beneden gaat. A. dat zagen we zelf ook; B. als je niks intelligenters kunt verzinnen, kun je beter eerbiedig je mond houden en meelezen. C snap je eigenlijk wel hoe beleggen werkt of is dat op het VMBO niet uitgelegd.)

excuses, maar ik kan niet tegen domheid

[verwijderd] 28 juni 2007 15:16

mijn dank voor je lovende woorden alleen wat bereft mijn opleiding zat je fout
ik nooit niet enige vorm van opleiding genoten laat staan afgemaakt
ik bespeur in je reactie toch wel wat teleurstelling in het aandeel octo?
sorry ik kan niet tegen wijsneuzen die anderen hun wil opleggen

[verwijderd] 29 juni 2007 09:51

GGD start hepatitis C campagne
Maastricht - De GGD Zuid Limburg is samen met de GGD Amsterdam deze week een speciale hepatitis C campagne begonnen. Tijdens deze campagne roepen beide GGD’en inwoners op om via een vragenlijst op www.heptest.nl te achterhalen of de kans bestaat dat ze besmet zijn met het hepatitis C virus. Veel mensen zijn besmet met het virus zonder dit zelf te weten. Hepatitis C kan leiden tot een ernstige ziekte, wanneer de besmetting niet tijdig wordt ontdekt. De bloedtest, die aantoont of het virus in het bloed zit, is voor inwoners van de regio Zuid-Limburg en Amsterdam tijdens deze campagne gratis.

Geschat wordt dat in Zuid-Limburg circa 600 tot 2400 burgers besmet zijn met het hepatitis C, zonder het te weten. Het hepatitis C virus vindt men bij jong én oud. In tegenstelling tot hepatitis A of B is er voor hepatitis C geen vaccin. Er bestaat wel een goede behandeling.

Het hepatitis C virus wordt overgedragen door contact met besmet bloed. Je kunt het op diverse manieren krijgen. De één raakt 15 jaar geleden besmet door een bloed-transfusie, de ander door een tatoeage van vorig jaar of door een operatie in een ander land. Zo zijn er nog veel meer manieren om hepatitis C op te lopen.

Bijzonder aan een hepatitis C infectie is dat je aanvankelijk meestal niets merkt. Er zijn vrijwel geen lichamelijke klachten. Toch kan het virus de lever ernstig aantasten. Dit kan leiden tot leverfalen, leverkanker en sterfte. Het kan wel tot 30 jaar na besmetting duren voordat mensen lichamelijke klachten krijgen. Dan is het soms te laat voor een behandeling.

Onlangs is de behandeling tegen hepatitis C erg verbeterd. Bij tijdige ontdekking van het virus kan men veel doen om ernstige schade aan de lever te voorkomen. Ook kan men voorkomen dat het virus wordt overgedragen naar andere mensen. Daarom is het erg belangrijk om (tijdig) te weten of iemand een hepatitis C infectie heeft.

35 Posts, Pagina: « 1 2 | Laatste

Aantal posts per pagina: 20 50 100 | Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met uw e-mailadres en wachtwoord.

Direct naar Forum

Markt vandaag

AEX 909,03 -2,31 -0,25% 11:09


Germany40^	22.870,60	-0,60%
BEL 20	4.423,82	-1,02%
Europe50^	5.431,69	-0,67%
US30^	42.454,80	-0,80%
Nasd100^	19.959,90	-1,13%
US500^	5.710,90	-1,00%
Japan225^	36.771,30	-1,37%
Gold spot	2.908,22	-0,06%
EUR/USD	1,0856	+0,06%
WTI	67,22	+0,34%